Cargando…

Metformin Can Enhance the Inhibitory Effect of Olaparib in Bladder Cancer Cells

BACKGROUND: Bladder cancer is a common urinary system tumor. In the treatment of clinical patients, it is particularly important to find an effective treatment method to inhibit tumor growth. The world's first PARP inhibitor olaparib is mainly used for the treatment of BRCA1/BRCA2 mutated tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chi, Bao-Jin, Sun, Yao, Quan, Ling-Li, Zhao, Jin-Tao, Wei, Bo, Wang, Shu-Qiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249502/ https://www.ncbi.nlm.nih.gov/pubmed/35783012 http://dx.doi.org/10.1155/2022/5709259

Ejemplares similares

Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines
por: Gralewska, Patrycja, et al.
Publicado: (2021)

Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer
por: Wang, Zhenwei, et al.
Publicado: (2021)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2015)

Olaparib nanoparticles potentiated radiosensitization effects on lung cancer
por: Wu, Min, et al.
Publicado: (2018)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Olaparib: Transcending mutational barriers
por: Chandna, Abhishek
Publicado: (2019)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2017)

Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
por: Mukherjee, Shibani, et al.
Publicado: (2020)

Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways
por: Pan, Qi, et al.
Publicado: (2015)

Enhanced Anti-Cancer Effect of Folate-Conjugated Olaparib Nanoparticles Combined with Radiotherapy in Cervical Carcinoma
por: Li, Dong, et al.
Publicado: (2020)

Activation of autophagy flux by metformin downregulates cellular FLICE–like inhibitory protein and enhances TRAIL- induced apoptosis
por: Nazim, Uddin MD, et al.
Publicado: (2016)

The Antidiabetic Drug Metformin Inhibits the Proliferation of Bladder Cancer Cells in Vitro and in Vivo
por: Zhang, Tao, et al.
Publicado: (2013)

The combination of olaparib and camptothecin for effective radiosensitization
por: Miura, Katsutoshi, et al.
Publicado: (2012)

Olaparib and Doxorubicin Co-Loaded Polypeptide Nanogel for Enhanced Breast Cancer Therapy
por: Liu, Yanhong, et al.
Publicado: (2022)

Olaparib in the Setting of Radiotherapy-Associated Sarcoma: What Can Precision Medicine Offer For Rare Cancers?
por: Hamdan, Diaddin, et al.
Publicado: (2023)

Comparison of Adverse Reactions Caused by Olaparib for Different Indications
por: Zhou, Yujing, et al.
Publicado: (2022)

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report
por: Xie, Yuan, et al.
Publicado: (2016)

Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer
por: Quiñonero, Francisco, et al.
Publicado: (2023)

Discovery of Ruthenium(II) Metallocompound and Olaparib Synergy for Cancer Combination Therapy
por: Yusoh, Nur Aininie, et al.
Publicado: (2023)

Metformin for the Prevention of Bladder Cancer Recurrence: Is it Effective?
por: Heidari, Fatemeh, et al.
Publicado: (2016)

New insight for metformin against bladder cancer
por: EL-Arabey, Amr Ahmed
Publicado: (2017)

Profile of olaparib in the treatment of advanced ovarian cancer
por: Chase, Dana M, et al.
Publicado: (2016)

Olaparib-Induced Immune-Mediated Liver Injury
por: Alshelleh, Mohammad, et al.
Publicado: (2022)

A case of hand-foot syndrome with olaparib
por: da Costa, Rafael Everton Assunção Ribeiro, et al.
Publicado: (2022)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
por: Mahdi, Haider, et al.
Publicado: (2021)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Metformin Use on Incidence and Oncologic Outcomes of Bladder Cancer Patients With T2DM: An Updated Meta-Analysis
por: Liu, Chen-Qian, et al.
Publicado: (2022)

Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice
por: Chen, Li-Mei, et al.
Publicado: (2022)

High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model
por: Peng, Mei, et al.
Publicado: (2016)

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
por: Fok, Jacqueline H. L., et al.
Publicado: (2019)

Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells
por: Zhao, Hui, et al.
Publicado: (2018)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Novel Albumin Nanoparticle Enhanced the Anti-Insulin-Resistant-Hepatoma Activity of Metformin
por: Lu, Zhong, et al.
Publicado: (2020)

Myo-Inositol Potentiates the Inhibitory Effect of Metformin on Prolactin Levels
por: Krysiak, Robert, et al.
Publicado: (2023)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
por: Mansouri, Anita, et al.
Publicado: (2021)

Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells
por: de Castro e Gloria, Helena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1hqi4pk3h7ql8tgol6o7jjskc4